AVITA Medical Future Growth
Future criteria checks 5/6
AVITA Medical is forecast to grow earnings and revenue by 77.7% and 26.6% per annum respectively. EPS is expected to grow by 79.7% per annum. Return on equity is forecast to be 1.2% in 3 years.
Key information
77.7%
Earnings growth rate
79.7%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 26.6% |
| Future return on equity | 1.2% |
| Analyst coverage | Good |
| Last updated | 21 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 136 | -2 | 16 | 19 | 8 |
| 12/31/2025 | 104 | -25 | -16 | -14 | 10 |
| 12/31/2024 | 68 | -56 | -48 | -42 | 10 |
| 9/30/2024 | 60 | -57 | -60 | -52 | N/A |
| 6/30/2024 | 54 | -50 | -58 | -53 | N/A |
| 3/31/2024 | 51 | -45 | -52 | -50 | N/A |
| 12/31/2023 | 50 | -35 | -39 | -38 | N/A |
| 9/30/2023 | 45 | -34 | -32 | -31 | N/A |
| 6/30/2023 | 41 | -31 | -25 | -24 | N/A |
| 3/31/2023 | 37 | -26 | -20 | -19 | N/A |
| 12/31/2022 | 34 | -27 | -20 | -19 | N/A |
| 9/30/2022 | 32 | -30 | -21 | -21 | N/A |
| 6/30/2022 | 30 | -30 | -19 | -18 | N/A |
| 3/31/2022 | 32 | -29 | -19 | -19 | N/A |
| 12/31/2021 | 33 | -25 | -19 | -18 | N/A |
| 9/30/2021 | 31 | -22 | -20 | -19 | N/A |
| 6/30/2021 | 29 | -27 | -27 | -26 | N/A |
| 3/31/2021 | 23 | -35 | -29 | -28 | N/A |
| 12/31/2020 | 18 | -44 | -28 | -27 | N/A |
| 9/30/2020 | 16 | -49 | -27 | -26 | N/A |
| 6/30/2020 | 14 | -42 | -24 | -23 | N/A |
| 3/31/2020 | 12 | -36 | -24 | -23 | N/A |
| 12/31/2019 | 11 | -28 | -22 | -21 | N/A |
| 9/30/2019 | 8 | -23 | -22 | -21 | N/A |
| 6/30/2019 | 5 | -25 | -20 | -19 | N/A |
| 3/31/2019 | 4 | -22 | -19 | -18 | N/A |
| 12/31/2018 | 2 | -18 | -14 | -13 | N/A |
| 9/30/2018 | 1 | -15 | -13 | -13 | N/A |
| 6/30/2018 | 1 | -13 | N/A | -13 | N/A |
| 3/31/2018 | 1 | -12 | N/A | -11 | N/A |
| 12/31/2017 | 1 | -11 | N/A | -9 | N/A |
| 9/30/2017 | 1 | -10 | N/A | -8 | N/A |
| 6/30/2017 | 1 | -9 | N/A | -7 | N/A |
| 3/31/2017 | 1 | -8 | N/A | -6 | N/A |
| 12/31/2016 | 1 | -7 | N/A | -6 | N/A |
| 9/30/2016 | 1 | -8 | N/A | -6 | N/A |
| 6/30/2016 | 1 | -8 | N/A | -6 | N/A |
| 3/31/2016 | 1 | -8 | N/A | -7 | N/A |
| 12/31/2015 | 1 | -7 | N/A | -7 | N/A |
| 9/30/2015 | 1 | -6 | N/A | -5 | N/A |
| 6/30/2015 | 1 | -6 | N/A | -5 | N/A |
| 3/31/2015 | 1 | -5 | N/A | -4 | N/A |
| 12/31/2014 | 1 | -5 | N/A | -4 | N/A |
| 9/30/2014 | 2 | -5 | N/A | -5 | N/A |
| 6/30/2014 | 3 | -5 | N/A | -7 | N/A |
| 3/31/2014 | 3 | -6 | N/A | -7 | N/A |
| 12/31/2013 | 3 | -7 | N/A | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 51KA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: 51KA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 51KA is expected to become profitable in the next 3 years.
Revenue vs Market: 51KA's revenue (26.6% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 51KA's revenue (26.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 51KA's Return on Equity is forecast to be low in 3 years time (1.2%).